{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 42,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a structured list format to present clinical safety findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/37",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.28,
        "y": 0.22
      },
      "kind": "list",
      "text": "Virtually all (99%) adverse events (AEs) were mild-to-moderate in severity; Minimal (2.5%) treatment emergent AEs (TEAEs) led to study withdrawal; No drug-related serious adverse events (SAEs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "295d1b67-cb93-43d3-b52b-b48229d4e433",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.28,
        "y": 0.45
      },
      "kind": "list",
      "text": "Only SAE was in 50 µg dose group and deemed unrelated; AE profile consistent with historical studies and drug class",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e79d30f-0b6d-496f-b839-4bb3b13639b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.28,
        "y": 0.62
      },
      "kind": "list",
      "text": "No suicidal or self-injurious behavior; ≤ 2 participant per arm reported suicidal ideation during the study; No indication of increased suicidality or suicide-related risk",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49f83502-9121-4b44-9ac6-d8ee5e9f822f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.16,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Source: Study MMED008 internal study documents and calculations. Safety population. 2. One serious adverse event (SAE) was observed in the 50 µg dose group: panic attack on study day 98 that was deemed not related to treatment. 3. Suicidality assessment based on reported adverse events.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b11d4b89-64d6-4b36-952f-8854d5d9a2f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.924,
        "x": 0.038,
        "y": 0.05
      },
      "kind": "title",
      "text": "MM120 was Well-tolerated with Mostly Transient, Mild-to-Moderate Adverse Events Consistent with Drug Class Expectations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "162eaa72-cdf2-447b-ba5d-410e6997cbd0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f5606dc9-5748-4a18-8daf-29b59bb63104",
      "evidence": "list/bullet: Virtually all (99%) adverse events (AEs) were mild-to-moderate in severity; Minimal (2.5%) treatment emergent AEs (TEAEs) led to study withdrawal; No drug-related serious adverse events (SAEs)",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}